MH. Toward a very brief self-report to assess the core symptoms of depression (VQIDS-SR 5 ).
Introduction
Measurement-based care (MBC) has been shown to improve the outcomes of patients treated for depression (1) . Brief and convenient symptom and side-effect self-report measures are essential for effective MBC. Currently, the 9-item Patient Health Questionnaire (PHQ-9) (2) and the 16-item (nine domains) Quick Inventory of Depressive Symptomatology -Self-Report (QIDS-SR 16 ) (3) are among the self-report measures commonly used to implement MBC in primary and psychiatric care settings. While both measures are relatively brief, there may be ways to further curtail assessment time, and thus facilitate the adoption of MBC in routine practice (4) . Additionally, some criterion symptoms of a major depressive episode may simply be medication side-effects (e.g., insomnia, lethargy). Thus, the rating of these symptoms may actually interfere with detecting a positive response to treatment in other core depressive symptoms.
Bech et al. found that a subset of six core depressive symptoms extracted from the 17-item Hamilton Rating Scale for Depression (HRSD 17 ) accounted for 54.8% of the variance attributable to the HRSD 17 (5) (6) (7) . Further, Kyle et al. found that the briefer HRSD 6 was better at detecting remission than the longer versions of the Hamilton Rating Scale (8) . These findings suggest that a shorter version of the report may be just as effective while taking only one-third of the time to complete, thereby making it more practical to implement clinically. As such, it is logical to investigate an analogous question: Can fewer items extracted from the QIDS-SR 16 be sufficient and time-effective to gauge the symptomatic effects of treatment for depression?
To that end, we created the Very Quick Inventory of Depressive Symptomatology (VQIDS-SR 5 ) by extracting five core depression domains from the QIDS-SR 16 : sad mood, self-outlook, involvement, fatigue, and psychomotor slowing. These items reflect those identified as the depressive symptoms in Bech's HRSD 6 (5), but excludes the anxiety item, which has the smallest loading when using principle component analysis (7). It was not deemed core to major depressive disorder, but rather an associated symptom, and as such, it is not in the QIDS-SR 16 .
This report evaluates the psychometric features (internal consistency, concurrent validity, dimensionality, and sensitivity to change) of the VQIDS-SR 5 , as well as thresholds that define response and remission as compared to the QIDS-SR 16 . The data for this report came from individuals who participated in the Combining Medications to Enhance Depression Outcomes (CO-MED) study, a single-blind, multi-center, randomized trial that compared three different medication treatments in out-patients with non-psychotic depression treated over 12 weeks (9) .
Material and methods
The CO-MED study protocol and procedures were approved by the Institutional Review Board at the University of Texas Southwestern Medical Center (national coordinating center), the University of Pittsburgh (data coordinating center), and each participating center and clinic. Details of the study design, measurements, and primary outcomes are available elsewhere (9) .
Study participants met criteria for chronic (current episode >2 years) or recurrent non-psychotic depression with a current episode lasting at least 2 months and a score ≥16 on the HRSD 17 . The study enrolled 665 participants from six primary and nine psychiatry care sites. Participants were assigned to one of three different treatments in a 1 : 1 : 1 ratio: (i) escitalopram plus placebo, (ii) sustained-release bupropion plus escitalopram, and (iii) extended-release venlafaxine plus mirtazapine. Study physicians implemented MBC (1, 4) at every visit to adjust participants' medication dosage based on scores from the 16-item Quick Inventory of Depressive Symptomatology -Clinician-rated (QIDS-C 16 ) Scale (3) and the Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) Scale (10) . The 30-item Inventory of Depressive Symptomatology -Clinicianrated (IDS-C 30 ) Scale (11) and QIDS-SR 16 measurements were collected at baseline (week 0) and at follow-up visits (weeks 1, 2, 4, 6, 8, 10, and 12). The QIDS-C 16 , 6-item Inventory of Depressive Symptomatology (IDS-C 6 ) Scale (12) , and VQIDS-C 5 were derived from the IDS-C 30. Subsequently, the VQIDS-SR 5 was extracted from the QIDS-SR 16 core symptom items: sad mood, selfoutlook, involvement, fatigue, and psychomotor slowing.
Statistical analysis
The statistical analysis was divided into four parts. First, we evaluated the psychometric properties of the VQIDS-SR 5 questionnaire using principal component analysis and Mokken analysis (13) . To determine the number of factors present in the VQIDS-SR 5 , both the parallel analysis and Velicer's minimum average partial (MAP) tests were performed. The tests were conducted and evaluated at four time points: baseline (week 0), critical decision point (week 4), middle of treatment (week 6), and end of acute treatment (week 12) (14) . We then evaluated the performance of the VQIDS-SR 5 and how it compares to the QIDS-SR 16 . Cronbach's coefficient alpha was used to examine the reliability of both measures and individual items from each participant at each time point (15) . Mokken analysis allows for the use of the automated item selection algorithm (AISA) and the computation of Loevinger coefficient of homogeneity (H) (13) .
The second analysis compared the relative sensitivities of the VQIDS-SR 5 and QIDS-SR 16 to their treatment effect over time. To compare the two scales' sensitivities to change in this trial, two mixed-model analyses were conducted using the VQIDS-SR 5 and the QIDS-SR 16 as outcomes. The model was limited to the main effects of treatment group (A, B, C), time (weeks 0, 1, 2, 4, 6, 8, 10, and 12), and the group-by-time interaction. We also report three model-fit indices: the À2 log likelihood, the Akaike's information criterion (AIC) and the Bayesian information criterion (BIC). These measures are based on the residual variance that is not explained by a model. Thus, a lower number indicates a better fit and greater sensitivity to change over time.
The third set of analyses were conducted to examine the comparability of the VQIDS-SR 5 and the standard QIDS-SR 16 in terms of their estimation of the two most common categorical clinical outcomes: response (defined as 50% symptom reduction from baseline) and remission (defined as QIDS-SR 16 score of 5 or less; VQIDS-SR 5 score of 3 or less).
Finally, to understand the relationship between the VQIDS-SR 5 and clinician-rated scales, we report correlations between each of the two selfreports, VQIDS-SR 5 and QIDS-SR 16 , and the IDS-C 30 , QIDS-C 16 , IDS-C 6 , and VQIDS-C 5 . These were all collected at week 6 to provide a more robust range of scores than at baseline, while being early enough in the study to minimize dropouts.
Results Table 1 provides basic clinical and demographic information of the sample population.
Psychometric evaluation
The principle component analysis revealed a single-factor structure for the VQIDS-SR 5 . All five items loaded on a single factor that ranged from 0.77 to 0.67 when analyzing data collected at week 6. Based on both parallel analysis and the MAP test, the VQIDS-SR 5 is best described as a singlefactor measure at baseline, week 4, week 6, and week 12. Based on the AISA, all five items load on a single factor for all weeks, except for self-outlook at the baseline visit. The H coefficients ranged from 0.33 at baseline to 0.53 at week 12, indicating better discriminate ability of the scale over the course of treatment.
Internal consistency of the VQIDS-SR 5 was measured using Cronbach's alpha, which reported values ranging from 0.67 at baseline to 0.81 at week 12. Omitted Item Statistics showed that all VQIDS-SR 5 items had a good fit based on improvement to the internal reliability throughout time. We also calculated Cronbach's alpha for the QIDS-SR 16 at different time intervals. Results ranged from 0.70 at week 0 to 0.81 at week 12. These results are similar to the ones observed for the VQIDS-SR 5 ( Table 2 ).
Sensitivity to treatment effects
The model using the VQIDS-SR 5 showed no significant main effect for group, a main effect for time, and no group-by-time interaction. The same pattern of results was found when the QIDS-SR 16 was evaluated, demonstrating that the shorter VQIDS-SR 5 could detect the same changes as were found using the full scale (Table 3 ).
An additional test was performed to compare the two measures based on the amount of systematic change that was not explained by the model. Specifically, the sensitivity of both mixed effect models was measured by calculating residual variance. For the VQIDS-SR 5 , the fits statistics were (Fig. 1a and b) .
Relations among self-report and clinician-rated scales
The correlations among the clinician-rated and self-report forms of the severity measures were examined at week 6. The correlation between the self-report scales, the VQIDS-SR 5 and the QIDS-SR 16 , was r = 0.90. The correlation between the VQIDS-SR 5 and the IDS-C 30 , the clinician-rated scale with the most items, was r = 0.57, which is comparable to the r = 0.67 correlation between the longer QIDS-SR 16 and the IDS-C 30. While there is meaningful overlap between the self-report and the clinician-rated scales, there are also clear differences. The overlap and differences between selfreport scales and clinician-rated scales appear to be proportionate to the length of the scale (Table 4) .
Discussion
To our knowledge, this is the first report to evaluate a much shorter self-report scale for measuring the core symptoms of major depression using a 5-item version of the Quick Inventory of Depressive Symptoms (VQIDS-SR 5 ). The VQIDS-SR 5 has a single-factor structure and an internal consistency comparable to the longer QIDS-SR 16 . The VQIDS-SR 5 was as sensitive to change as the QIDS-SR 16 and provided a better measure of change to treatment. Furthermore, in this initial study, the VQIDS-SR 5 was better able to differentiate responders from non-responders at an earlier time point than the QIDS-SR 16 . Finally, the 5-item self-report was comparable to the 5-item clinicianrated version, as demonstrated by a strong correlation between both tools. Together, results suggest that the VQIDS-SR 5 may be a useful alternative or supplement to the longer QIDS-SR 16 .
While there is no prior report specific to a shortened version of the QIDS 16 with which to compare our study, the concept of shortening a longer scale to focus on core symptoms of depression has previously been reported using other clinical rating scales. For example, Bech et al. (6, 7) Group F (2, 630) = 0.44, P < 0.65 F (2, 630) = 1.76, P < 0.18 Time F (7, 3471) = 184.18, P < 0.0001 F (7, 3471) = 209.01, P < 0.0001 Group by Time and tested a 6-item HRSD subscale to measure the core symptoms of depression, which has been reported as more robust and sensitive to change than its parent scale (16 (19) reported are depressed mood, feelings of guilt, suicide, work and activities, psychic anxiety, somatic anxiety, and somatic symptoms. These shorter scales were aimed at identifying specific items that accounted for the greatest amount of the variance in outcome as assessed by the longer parent scale (20) . This coalescence of studies indicates that the core symptoms are pivotal indicators of therapeutic effect, giving credence to their use as a primary outcome tool.
This initial report suggests that the 5-item version of the QIDS-SR is adequately sensitive to change, such that it may suffice for the implementation of MBC in practice and between visits. That speculation, however, requires prospective testing. Clearly, a focus on the core symptoms limits the information that a clinician may take into consideration with MBC. For example, the presence of hypersomnia/insomnia or weight gain/loss may affect medication choice, yet these symptoms are not addressed on the VQIDS-SR 5 . It is possible that side-effects may go unreported or dose adjustments may be poorly informed. On the other hand, a sharp focus on the core symptoms appears to detect positive change in depressive symptoms early in the course of treatment.
This secondary analysis has several limitations. The VQIDS-SR 5 was compared to the parent QIDS-SR 16 from which the 5-item version was extracted, which clearly inflates the similarity between these two measures. Second, this relatively small sample of convenience drawn from a single study makes generalizability uncertain. Third, while we emulated the Bech et al. HRSD 6 (6) item test, we did not carefully evaluate the pros and cons of including vs. excluding the anxiety metric. Further evaluation of this question is necessary. Lastly, we have not yet compared the VQIDS-SR 5 to other commonly used scales. To conclude, the VQIDS-SR 5 , a 5-item self-report using selected items from the QIDS-SR 16, is quick, easy and provides a reliable and valid measure of the severity of the core symptoms of depression. It is also sensitive to early treatment change and may be a worthwhile report to employ clinically.
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